학술논문
Frequency and economic burden of exacerbations in inhaled corticosteroid/long-acting beta-agonist-treated patients with asthma: A retrospective US claims study.
Document Type
Academic Journal
Author
Duh MS; Analysis Group, Inc., Boston, MA, USA.; Roberts MH; University of New Mexico, Albuquerque, NM, USA.; Rothnie KJ; GSK, R&D Global Medical, Brentford, Middlesex, UK.; Cheng WY; Analysis Group, Inc., Boston, MA, USA.; Thompson-Leduc P; Analysis Group, Inc., Boston, MA, USA.; Zhang S; GSK, Collegeville, PA, USA.; Czira A; GSK, R&D Global Medical, Brentford, Middlesex, UK.; Slade D; GSK, Research Triangle Park, NC, USA.; Greatsinger A; Analysis Group, Inc., Boston, MA, USA.; Zhang A; Analysis Group, Inc., Boston, MA, USA.; Mapel D; University of New Mexico, Albuquerque, NM, USA. Electronic address: Dmapel@comcast.net.
Source
Publisher: Elsevier Country of Publication: England NLM ID: 8908438 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1532-3064 (Electronic) Linking ISSN: 09546111 NLM ISO Abbreviation: Respir Med Subsets: MEDLINE
Subject
Language
English
Abstract
Introduction: Despite adherence to inhaled corticosteroid/long-acting β 2 -agonist (ICS/LABA) therapy, many patients with asthma experience moderate exacerbations. Data on the impact of moderate exacerbations on the healthcare system are limited. This study assessed the frequency and economic burden of moderate exacerbations in patients receiving ICS/LABA.
Methods: Retrospective, longitudinal study analyzed data from Optum's de-identified Clinformatics® Data Mart Database recorded between October 1, 2015, and December 31, 2019. Eligibility criteria included patients ≥18 years of age with ≥1 ICS/LABA claim and ≥1 medical claim for asthma in the 12 months pre-index (first ICS/LABA claim). Primary objectives included describing moderate exacerbation frequency, and associated healthcare resource utilization (HRU) and costs. A secondary objective was assessing the relationship between moderate exacerbations and subsequent risk of severe exacerbations. Patients were stratified by moderate exacerbation frequency in the 12 months post index. Moderate exacerbations were identified using a newly developed algorithm.
Results: In the first 12 months post index 61.6% of patients experienced ≥1 moderate exacerbation. Mean number of asthma-related visits was 4.1 per person/year and median total asthma-related costs was $3544. HRU and costs increased with increasing exacerbation frequency. Outpatient and inpatient visits accounted for a similar proportion of these costs. Moderate exacerbations were associated with an increased rate and risk of future severe exacerbations (incidence rate ratio, 1.56; hazard ratio, 1.51 [both p < 0.001]).
Conclusions: This study highlighted that a high proportion of patients continue to experience moderate exacerbations despite ICS/LABA therapy and subsequently experience increased economic burden and risk of future severe exacerbations.
Competing Interests: Declaration of competing interest MSD, WYC, PT-L, AG, and AZ are employees of Analysis Group, Inc, a consulting company that received research funds from GSK to conduct this study. MHR received research funds from Analysis Group for this study. KJR, SZ, and DS are employees of GSK and hold stocks or shares in GSK. AC was an employee of GSK at the time of the study. DM has received research grant funding from AstraZeneca, GSK, and Sunovion Pharmaceuticals, and has served as a consultant to AstraZeneca, GSK, Theravance, and Novartis.
(Copyright © 2024. Published by Elsevier Ltd.)
Methods: Retrospective, longitudinal study analyzed data from Optum's de-identified Clinformatics® Data Mart Database recorded between October 1, 2015, and December 31, 2019. Eligibility criteria included patients ≥18 years of age with ≥1 ICS/LABA claim and ≥1 medical claim for asthma in the 12 months pre-index (first ICS/LABA claim). Primary objectives included describing moderate exacerbation frequency, and associated healthcare resource utilization (HRU) and costs. A secondary objective was assessing the relationship between moderate exacerbations and subsequent risk of severe exacerbations. Patients were stratified by moderate exacerbation frequency in the 12 months post index. Moderate exacerbations were identified using a newly developed algorithm.
Results: In the first 12 months post index 61.6% of patients experienced ≥1 moderate exacerbation. Mean number of asthma-related visits was 4.1 per person/year and median total asthma-related costs was $3544. HRU and costs increased with increasing exacerbation frequency. Outpatient and inpatient visits accounted for a similar proportion of these costs. Moderate exacerbations were associated with an increased rate and risk of future severe exacerbations (incidence rate ratio, 1.56; hazard ratio, 1.51 [both p < 0.001]).
Conclusions: This study highlighted that a high proportion of patients continue to experience moderate exacerbations despite ICS/LABA therapy and subsequently experience increased economic burden and risk of future severe exacerbations.
Competing Interests: Declaration of competing interest MSD, WYC, PT-L, AG, and AZ are employees of Analysis Group, Inc, a consulting company that received research funds from GSK to conduct this study. MHR received research funds from Analysis Group for this study. KJR, SZ, and DS are employees of GSK and hold stocks or shares in GSK. AC was an employee of GSK at the time of the study. DM has received research grant funding from AstraZeneca, GSK, and Sunovion Pharmaceuticals, and has served as a consultant to AstraZeneca, GSK, Theravance, and Novartis.
(Copyright © 2024. Published by Elsevier Ltd.)